

# Standardization of Criteria for Adolescent Idiopathic Scoliosis Brace Studies

SRS Committee on Bracing and Nonoperative Management

B. Stephens Richards, MD,\* Robert M. Bernstein, MD,† Charles R. D'Amato, MD,‡  
and George H. Thompson, MD§

## Study Design. Literature review.

**Objective.** To establish consistent parameters for future adolescent idiopathic scoliosis bracing studies so that valid and reliable comparisons can be made.

**Summary of Background Data.** Current bracing literature lacks consistency for both inclusion criteria and the definitions of brace effectiveness.

**Methods.** A total of 32 brace treatment studies and the current bracing in adolescent idiopathic scoliosis proposal were analyzed to: (1) determine inclusion criteria that will best identify those patients most at risk for progression, (2) determine the most appropriate definitions for bracing effectiveness, and (3) identify additional variables that would provide valuable information.

**Results.** Early brace studies lacked clarity in their inclusion criteria. In more recent studies, inclusion criteria have narrowed considerably to include primarily those patients most at risk for curve progression who may benefit from the use of a brace. Brace effectiveness was usually defined by various degrees of curve progression at maturity. Less frequently, it was defined by the resultant curve magnitude at maturity, whether or not surgical intervention was needed, or if there was change to another brace.

**Conclusions.** Optimal inclusion criteria for future adolescent idiopathic scoliosis brace studies consist of: age is 10 years or older when brace is prescribed, Risser 0–2, primary curve angles 25°–40°, no prior treatment, and, if female, either premenarchal or less than 1 year postmenarchal. Assessment of brace effectiveness should include: (1) the percentage of patients who have ≤5° curve progression and the percentage of patients who have ≥6° progression at maturity, (2) the percentage of patients with curves exceeding 45° at maturity and the percentage who have had surgery recommended/undertaken, and (3) 2-year follow-up beyond maturity to determine the percentage of patients who subsequently undergo surgery. All patients, regardless of subjective reports on compliance, should be included in the results (intent to treat).

Every study should provide results stratified by curve type and size grouping.

**Key words:** scoliosis, bracing, nonoperative treatment.  
**Spine 2005;30:2068–2075**

Brace treatment has been used for the nonoperative treatment of adolescent idiopathic scoliosis (AIS) for nearly 45 years. During this period, there have been numerous studies in the literature that summarize the results of treatment.<sup>1–35</sup> Many of these reports support the effectiveness of an orthosis in preventing curve progression and the need for surgical intervention.<sup>1–4,7–10,13–15,17–24,26–30,32–35</sup> However, there are other studies that suggest bracing may not be effective.<sup>6,11,12,16,25,31</sup> A review of the literature on the effectiveness of an orthosis for AIS shows that inclusion criteria vary greatly from one study to the next. The age range, inclusion of both males and females, Risser sign, curve magnitude, and lack of stratification of results regarding curve pattern, curve size, and maturity can be quite different, which makes comparisons among studies difficult. These studies are summarized in Table 1.

As a greater understanding of the natural history of AIS has been gained, patients who are most at risk for curve progression have been better identified.<sup>36–42</sup> Subsequently, reports over the past decade have improved, primarily through the exclusion of patients who are known to have a low risk for progression. Patients who were skeletally mature at orthotic initiation, those with curves so small that progression was unlikely, those who had curves so large that nonoperative treatment would be ineffective, those who have had prior treatments, and nonidiopathic (such as congenital or neuromuscular deformities) should be excluded. Unfortunately, more recent studies still differ significantly among their inclusion criteria, thus making comparisons difficult.

Furthermore, there has been even less uniformity among the studies in defining what represents a success or failure of orthotic treatment. Some studies consider treatment a success only if curve progression does not exceed 5° by the time patients reach skeletal maturity. For others, it is less than 10°. Still others consider orthotic treatment successful if the curve is less than 45° at skeletal maturity, or if surgery was not necessary regardless of the amount of curve progression. This variation in

From the \*Department of Orthopaedic Surgery, Texas Scottish Rite Hospital for Children, Dallas, TX; †Department of Orthopaedic Surgery, Cedar-Sinai Medical Center, West Hollywood, CA; ‡Shriners Hospital, Portland, OR; and §Department of Orthopaedic Surgery, Case Western Reserve University, Cleveland, OH.

Acknowledgment date: October 13, 2004. First revision date: December 30, 2004. Second revision date: February 15, 2005. Acceptance date: February 15, 2005.

The manuscript submitted does not contain information about medical device(s)/drug(s).

No funds were received in support of this work. No benefits in any form have been or will be received from a commercial party related directly or indirectly to the subject of this manuscript.

Address correspondence and reprint requests to B. Stephens Richards, MD, Texas Scottish Rite Hospital for Children, 2222 Welborn Street, Dallas, TX 75219; E-mail: steve.richards@tsrh.org

**Table 1. Inclusion Criteria at Brace Prescription**

Investigators	No. Patients	Idiopathic Only	Age at Brace Initiation	Risser	Curve Size	No Prior RX (documented)	Gender	Type of Brace
Moe and Kettleson <sup>22</sup>	169	Yes	Infantile thru adolescence	From 0 to "capped"	<20°–>70°		Mixed	Milwaukee
Mellencamp <i>et al</i> <sup>21</sup>	47	Yes	9.5–17.5		17°–75°		Mixed	Milwaukee
Carr <i>et al</i> <sup>2</sup>	133	Yes	10.0–16.2		12°–68°		Mixed	Milwaukee
McCullough <i>et al</i> <sup>20</sup>	100	No*	3–17		<20°–>40°		Mixed	Miami TLSO
Emans <i>et al</i> <sup>7</sup>	295	Yes	4–18	0–4	20°–59°		Mixed	Boston
Green <sup>13</sup>	44	Yes	9.7–15	0–2	23°–49°		Mixed	Boston/Milwaukee
Hanks <i>et al</i> <sup>14</sup>	100	Yes	7.5–15.0	0–>2	<20°–>40°		Female	Wilmington
Peltonen <i>et al</i> <sup>27</sup>	162	Yes	10–17		25°–40°		Mixed	Boston
Montgomery and Willner <sup>23</sup>	244	Yes		0–3	>25°		Female	Boston/Milwaukee
Piazza and Bassett <sup>28</sup>	67	Yes	9.4–14.9	0–1	20°–39°		Mixed	Wilmington
Willers <i>et al</i> <sup>35</sup>	25	Yes	8–16		20°–55°		Mixed	Boston
Goldberg <i>et al</i> <sup>11</sup>	42	Yes	11.9–15	0	15°–35°		Female	Boston
Lonstein and Winter <sup>19</sup>	1020	Yes	10–17	0–>2	8°–82°	No Rx	Mixed	Milwaukee
Olafsson <i>et al</i> <sup>26</sup>	64	Yes	9.8–17.2	0–>2	22°–44°	No Rx	Mixed	Boston
Fernandez-Feliberti <i>et al</i> <sup>8</sup>	69	Yes	8–15		20°–42°	No Rx	Mixed	TLSO
Nachemson <i>et al</i> <sup>24</sup>	286	Yes	10–15	0–>2	25°–35°		Female	TLSO
Upadhyay <i>et al</i> <sup>33</sup>	85	Yes	8–15	0–3	20°–45°		Mixed	Milwaukee/TLSO
Allington and Bowen <sup>1</sup>	188	Yes	≥9	0, 1	10°–40°		Mixed	Wilmington
Noonan <i>et al</i> <sup>25</sup>	102	Yes	?	0–3	≤45°		Mixed	Milwaukee
Price <i>et al</i> <sup>29</sup>	98	Yes	10–14.7	0–2	25°–49°	No Rx	Mixed	Charleston
Katz <i>et al</i> <sup>17</sup>	319	Yes	10.2–16.9	0–2	25°–45°	No Rx	Mixed	Boston/Charleston
Howard <i>et al</i> <sup>15</sup>	170	Yes	≥10	0–4	19°–66°	No Rx	Mixed	TLSO/Milwaukee/Charleston
Wiley <i>et al</i> <sup>34</sup>	50	Yes	10–16	0–2	35°–45°	No Rx	Mixed	Boston
Karol <sup>16</sup>	112	Yes	10.6–16.9	0–3	18°–45°	No Rx	Male only	Milwaukee/Charleston/Boston
Katz and Durrani <sup>18</sup>	51	Yes	≥10	0–2	36°–45°	No Rx	Mixed	Boston
d'Amato <i>et al</i> <sup>4</sup>	102	Yes	10–16.5	0–2	20°–42°		Female	Providence
Danielsson and Nachemson <sup>5</sup>	127	Yes	10.9–18.4		12°–60°		Mixed	Milwaukee/Boston
Trivedi and Thomson <sup>32</sup>	42	Yes	10–15.1	0, 1	25°–40°	No Rx	Female	Charleston
Gepstein <i>et al</i> <sup>10</sup>	122	Yes	10–16	0–4	<25°–>39°		Mixed	Charleston/Boston
Coillard <i>et al</i> <sup>3</sup>	195	Yes	6–14	0–3	15°–50°		Mixed	SpineCor
Spoonamore <i>et al</i> <sup>31</sup>	71	Yes	10–16	0–3	25°–45°		Mixed	Rosenberger
Gabos <i>et al</i> <sup>9</sup>	55	Yes	≥10	0, 1	20°–45°		Female	Wilmington
Weinstein <i>et al</i> (written communication, August 2004)		Yes	10–15	0–2	25°–39°		Mixed	

\*Included 3 congenital and 4 neuromuscular.

RX = prescription; TLSO = thoracolumbosacral orthosis.

the definition of success used to judge orthotic effectiveness makes it nearly impossible to compare the results of treatment. These differences that exist among studies emphasize the need to adopt consistent parameters for future brace studies. As yet, previous efforts to fulfill this need have not had much impact toward improving consistency in the literature.<sup>30</sup>

The purposes of our study are to define consistent parameters for inclusion criteria for orthotic treatment of patients with AIS and to define consistent parameters to assess the effectiveness (outcomes) of treatment. These parameters could then serve as guidelines for all future AIS bracing studies to make comparisons among studies more valid and reliable. It is not the intention of this study to determine the efficacy of orthotic treatment for AIS.

## Materials and Methods

Natural history studies on skeletally immature patients with AIS were reviewed to identify the patient population most at risk for curve progression and those who are at relatively low risk for progression.<sup>36–42</sup> We identified 32 retrospective or prospective brace treatment studies and the current BrAIST study, which is a proposal by Weinstein *et al* (written communication, August 2004) for a randomized, prospective multicenter trial for bracing AIS *versus* no treatment.<sup>1–5,7–11,13–29,31–35</sup> To identify these studies, a MEDLINE search was performed using the key words “scoliosis,” “brace,” “orthosis,” and “nonoperative treatment.” To be included, the studies had to contain specific descriptions of their inclusion criteria. References from these pertinent articles were then examined to identify further relevant studies. The treatment inclusion criteria for each study were then recorded, including diagnoses, age range, gender, Ris-

**Table 2. Risk of Curve Progression Relative to Age\***

Age (yrs)	Curve Magnitude	
	5°–19°	20°–29°
≤10	45%	100%
11–12	23%	61%
13–14	8%	37%
≥15	4%	16%

Risk of curve progression >5° for chronologic age relative to curve magnitude.  
 \*Adapted with permission from *J Bone Joint Surg Br*.<sup>39</sup>

ser sign, curve magnitude, curve patterns, type of orthosis, and recommended wear schedule. The definitions of orthotic success or failure were recorded as well as whether orthotic effectiveness was determined at skeletal maturity or at latest follow-up. Additional variables were recorded if they appeared to provide useful information. The aforementioned data were used to formulate recommendations for inclusion and exclusion criteria for future studies on the orthotic treatment of AIS.

## Results

### Patients Most at Risk for Curve Progression

Most natural history studies that have examined curve progression involved females, primarily with thoracic curves. These patients' ages and initial curve magnitudes were factors closely related to the likelihood of curve progression (Tables 2, 3). Those patients with curves between 20° and 29° were significantly more likely to have more than 5° curve progression when compared with those in similar age groups with curves 5°–19°. This result was particularly true for younger females. Skeletal maturity, as determined by the Risser sign, was also important when considering the risk of curve progression. The likelihood of more than 5° progression is significantly higher for those patients who are skeletally immature (Table 4).

### Inclusion Criteria

The inclusion criteria in early studies were inconsistent and characterized by wide variations in patient's age at orthotic initiation, curve magnitude, and skeletal maturity (Table 1). Frequently, data were included from patients now known to be at low risk for curve progression or who were already beyond the point when surgery is now commonly recommended. Patient ages ranged from 4 to nearly 19 years, and those with advanced skeletal

**Table 3. Risk of Curve Progression Relative to Age\***

Curve Magnitude	Age (yrs)		
	10–12	13–15	≥16
<19°	25%	10%	0%
20°–29°	60%	40%	10%
30°–59°	90%	70%	30%
>60°	100%	90%	70%

Risk of curve progression >5° for chronologic age relative to curve magnitude.  
 \*Adapted with permission from Nachemson *et al*.<sup>43</sup>

**Table 4. Risk of Curve Progression Relative to Skeletal Maturity**

Risser Sign	Curve Magnitude	
	5°–19°	20°–29°
0–1	22%	68%
2, 3, 4	1.6%	23%

Risk of curve progression >5° for skeletal maturity relative to curve magnitude.  
 \*Adapted with permission from *J Bone Joint Surg Br*.<sup>39</sup>

maturity (Risser sign 3 and 4) and curves as small as 12° or as large as 68° were included in the data.

In more recent studies, inclusion criteria for patients considered brace candidates have become more consistent. Most patients are 10 years of age or older at brace initiation (fitting with the definition of AIS). Most patients are those who are most at risk for progression (*i.e.*, skeletally immature with Risser sign of 0, 1, or 2), although some recent reports still included more skeletally mature patients (Risser 3). The majority of studies include patients whose curve magnitudes were in the range of 20° to 45°. Of these, curves 20°–25° usually had documentation of progression. Nevertheless, during the last decade, some studies have still included curves as small as 10° or as large as 66°.

Although most reports include both females and males, the number of male patients generally has represented a small percentage of the patients. In a study by Karol<sup>16</sup> that reported on males only, bracing was found ineffective as a result, in part, of their increased curve stiffness and consistently poor brace compliance. Several reports have limited their population studies to females, avoiding any potentially confounding data introduced by the inclusion of male patients.<sup>4,9,11,14,23,24,32</sup>

Many studies specifically showed that there had been no previous treatment before initiation of the orthoses in their patients.<sup>8,15–19,26,29,32,34</sup> This factor is important because previous treatment could impact the patient's willingness to wear an orthosis or may have impacted the size and flexibility of the curve before the reporting. Only one report, from 1981, included patients with diagnoses other than idiopathic scoliosis.<sup>20</sup> All others were limited to idiopathic scoliosis.

### Definitions of Brace Effectiveness

Most commonly, orthotic effectiveness has been defined by the amount of curve progression that occurred up to the time of brace discontinuation (at skeletal maturity) (Table 5). Occasionally, effectiveness has been determined by the amount of curve progression that has occurred until the time of most recent followup, this usually being 1–3 years beyond skeletal maturity. The most frequent definition of bracing success was 5° or less curve progression at orthotic discontinuation (skeletal maturity). Conversely, if a curve progressed 6° or more, bracing was considered a failure. Less frequently, other studies have considered 10° or less curve progression to be

Table 5. Outcome of Brace Effectiveness

Investigators	Definition of Brace Effectiveness		Definition of Maturity (brace discontinued/ weaned at this time)	Noncompliant Patients	Average f/u After Maturity (when brace was discontinued)
	Success	Failure			
Moe and Kettleson <sup>22</sup>		Not defined	Bone age, Risser sign, height, menarche		
Mellencamp <i>et al</i> <sup>21</sup>		Not defined		Excluded	>5 yrs
Carr <i>et al</i> <sup>2</sup>		Not defined			8 yrs
McCollough <i>et al</i> <sup>20</sup>		Not defined	2 yrs after menarchal		None
Emans <i>et al</i> <sup>7</sup>	≤5° Progression	≥6° Progression	Cessation of growth, Risser 4 or 5		1.4 yrs
Green <sup>13</sup>	<5° Progression	≥5° Progression	Bone age, Risser 4	Included	1.8 yrs
Hanks <i>et al</i> <sup>14</sup>	<10° Progression	≥10° Progression	Risser 4		3.3 yrs
Peltonen <i>et al</i> <sup>27</sup>	≤5° Progression	≥6° Progression	"When growth stopped"		None
Montgomery and Willner <sup>23</sup>	<45° Curve	Progression of curve to >45°	Risser 4+		None
Piazza and Bassett <sup>28</sup>	<40° Curve	>40° Curve with ≥5° progression <u>or</u> surgery			5–13 yrs
Willers <i>et al</i> <sup>35</sup>		Not defined	2 yrs after menarchal	Excluded	8.5 yrs
Goldberg <i>et al</i> <sup>11</sup>	<10° Progression <45° curve size No surgery	≥10° Progression <u>or</u> ≥45° curve size <u>or</u> need for surgery			None
Lonstein and Winter <sup>19</sup>	<5° Progression	≥5° Progression <u>or</u> surgery <sup>2</sup>	No change in height on consecutive visits; Risser 4 or 5; 18 mos after menarchal		6 yrs (54% patients)
Olafsson <i>et al</i> <sup>26</sup>		Not defined	Risser 4 or bone age	Excluded	4.8 yrs
Fernandez-Feliberti <i>et al</i> <sup>8</sup>	<40° Curve	≥40° Curve at end of Rx <u>or</u> surgery			3.3 yrs
Nachemson <i>et al</i> <sup>24</sup>	≤5° Progression	≥6° Progression	Bone age		None
Upadhyay <i>et al</i> <sup>33</sup>	≤45° Curve and within 5° of the prebrace curve	≥6° Progression <u>or</u> surgery	Bone age or Risser		>2 yrs
Allington and Bowen <sup>1</sup>	<5° Progression	≥5° Progression	Risser 4 and 2 yrs after menarchal (boys: Risser 5)		1.5 yrs
Noonan <i>et al</i> <sup>25</sup>	(1) <5° Progression by maturity, (2) no surgery, (3) <10° progression at f/u	(1) ≥5° Progression by maturity, (2) surgery or 50° curve at f/u, (3) ≥10° progression at f/u			6.3 yrs
Price <i>et al</i> <sup>29</sup>	≤5° Progression at end of treatment	<b>Failures:</b> good->5° but ≤10°; fair->10° but no surgery or Δ brace; poor-surgery or Δ brace		Included	1.1 yrs
Katz <i>et al</i> <sup>17</sup>	≤5° Progression at end of Rx	≥6° Progression curve <u>or</u> surgery (subset)	"Skeletal maturity"	Included	1.6 yrs
Howard <i>et al</i> <sup>15</sup>		>6° Progression <u>or</u> >10° progression <u>or</u> surgery	Risser 4+		1.5 yrs
Wiley <i>et al</i> <sup>34</sup>	≤5° Progression	≥6° Progression <u>or</u> need for surgery	Risser 4–5		3.1 yrs
Karol <sup>16</sup>	≤5° Progression	≥6° Progression <u>or</u> curve size ≥50°/ surgery		Included	1.2 yrs
Katz and Durrani <sup>18</sup>	≤5° Progression	≥6° Progression <u>or</u> surgery (subset)	"Skeletal maturity"		2.7 yrs
d'Amato <i>et al</i> <sup>4</sup>	≤5° Progression	≥6° Progression (at f/u) <u>or</u> surgery performed	No growth at 2 consecutive visits 6 mos apart; Risser 4; 18 mos after menarchal	Included	2.6 yrs
Danielsson and Nachemson <sup>5</sup>		Not Defined	Risser 4		22 yrs
Trivedi and Thomson <sup>32</sup>	≤5° Progression at f/u	≥6° Progression <u>or</u> surgery necessary <u>or</u> changed brace	Risser 4 or no change in height over 2 consecutive visits 6 mos apart	Included	3 yrs
Gepstein <i>et al</i> <sup>10</sup>	≤5° progression by maturity	≥6° progression <u>or</u> surgery			1.9 yrs

(Table Continues)

Table 5. Continued

Investigators	Definition of Brace Effectiveness		Definition of Maturity (brace discontinued/ weaned at this time)	Noncompliant Patients	Average f/u After Maturity (when brace was discontinued)
	Success	Failure			
Coillard <i>et al</i> <sup>3</sup>	≤5° Progression	≥6° Progression	"Skeletal maturity" or 2 yrs after menarchal Risser 4	Excluded	2 yrs
Spoonamore <i>et al</i> <sup>31</sup>	(1) <5° Progression by maturity, (2) no surgery, (3) <10° progression at f/u	(1) ≥5° Progression by maturity, (2) surgery or 50° at f/u, (3) ≥10° progression at f/u			2.3 yrs
Gabos <i>et al</i> <sup>9</sup>		≥5° Progression from time that brace was discontinued to f/u	Risser 4–5	"Documented compliance"	14.6 yrs
Weinstein <i>et al</i> (written communication, August 2004)	<45° Curve size	≥45° Curve size	Maturity—cessation of growth in height (over 12 mos)		No

f/u = follow-up.

the threshold for success/failure. Most often, braces were discontinued, or the weaning process was begun, when the patients reached skeletal maturity. Maturity was defined in a variety of ways. Most commonly, radiographic parameters were used, such as the Risser sign 4 or "4+" (females) or 5 (males), or by bone age determined from wrist radiographs using the Gruelich and Pyle Atlas. Physiologic parameters were also used, but less frequently. If patients had either no change or <1 cm change in their standing height over 2 consecutive visits 6 months apart, they were considered mature. In females, maturity was considered achieved if the patient was either 18 months postmenarchal or 2 years postmenarchal. The median values of these maturity indicators (*i.e.*, Risser sign 4, <1 cm change in height, and 2 years postmenarchal) are closely related.<sup>44</sup>

Other parameters have also been used to assess the effectiveness of orthotic treatment. Instead of using skeletal maturity as the end-point for assessment, some studies examined the amount of curve progression that had occurred at latest follow-up, usually 1–3 years after skeletal maturity. Although it is obvious that curves would have a higher tendency to increase over this interval, the same thresholds defining brace failures were used (≥6° or ≥10° curve progression).

Still, other definitions of brace failure have been used. These definitions are not based on the degree of curve progression that may have occurred during treatment but rather focus on the magnitude that the curve has reached. Some investigators defined failure as the progression of a curve to a magnitude exceeding 45° either before or at skeletal maturity. This was considered the threshold when surgery is recommended. However, many patients do not undergo surgery at this point, and, for this reason, some studies considered an orthosis to

have failed only when surgery was recommended or undergone.

Two studies have combined several of these parameters used to assess brace effectiveness.<sup>25,31</sup> They assessed the percentage of patients who had a progression of 5° or more by skeletal maturity, the percentage who had undergone surgery or had curves 50° or higher at the latest followup, and the percentage who had 10° or more progression by the latest followup. The data were then combined, and the resulting summation was used to report on the effectiveness of orthotic treatment. Obviously, as more parameters are combined in studies, an orthosis will be appear less effective when compared to reports using single parameters.

#### Additional Useful Variables

Many studies reported on additional variables, many of which appeared to provide useful comparative information (Table 6). The data were often analyzed separately by curve pattern (thoracic only, thoracolumbar/lumbar, double curves), curve magnitude grouping (*i.e.*, 20°–29°, 25°–35°, 30°–39°, 35°–45°, and ≥40°), curve rotation, menarchal status, in-brace correction, and comparisons among Risser signs 0, 1, and 2 skeletal maturity. Only one study documented peak height velocity data.<sup>18</sup>

#### Discussion

Over the past 15 years, there have been numerous studies on the orthotic treatment of AIS. In addition to reports on the more established orthoses, such as the Milwaukee brace, Boston brace, Wilmington brace, and Charleston bending brace, newer orthoses, such as the Providence brace, SpineCor brace (The SpineCorporation Ltd., Chesterfield, UK) and Rosenberger brace, are being de-

**Table 6. Documentation of Potentially Useful Additional Variables**

Investigators	Curve Patterns	Stratifications		In-Brace Correction (curve flexibility)	Curve Rotation (measured by Nash-Moe, Perdriolle, both, or other methods)	Menarchal Status
		Curve Magnitude Grouping (i.e., 25–35, 36–45, 20–29, 30–39, >40)	Comparisons Among Risser Signs 0, 1, and $\geq 2$			
Moe and Kettleson <sup>22</sup>	Yes	Yes	No	Yes	No	No
Mellencamp <i>et al</i> <sup>21</sup>	No	No	No	Yes	No	No
Carr <i>et al</i> <sup>2</sup>	Yes	Yes	No	Yes	No	No
McCullough <i>et al</i> <sup>20</sup>	Yes	No	No	Yes	No	No
Emans <i>et al</i> <sup>7</sup>	Yes	Yes	No	Yes	Yes	No
Green <sup>13</sup>	Yes	No	No	No	No	No
Hanks <i>et al</i> <sup>14</sup>	Yes	Yes	No	Yes	No	Yes
Peltonen <i>et al</i> <sup>27</sup>	Yes	No	No	Yes	Yes	No
Montgomery and Willner <sup>23</sup>	Yes	Yes	No	No	No	Yes
Piazza and Bassett <sup>28</sup>	Yes	Yes	No	No	No	No
Willers <i>et al</i> <sup>35</sup>	Yes	No	No	Yes	Yes	No
Goldberg <i>et al</i> <sup>11</sup>	Yes	No	No	No	No	Yes
Lonstein and Winter <sup>19</sup>	Yes	Yes	Yes	Yes	Yes	No
Olafsson <i>et al</i> <sup>26</sup>	Yes	No	No	Yes	Yes	Yes
Fernandez-Feliberti <i>et al</i> <sup>8</sup>	Yes	No	No	No	No	No
Nachemson <i>et al</i> <sup>24</sup>	Yes	Yes	No	No	Yes	Yes
Upadhyay <i>et al</i> <sup>33</sup>	Yes	Yes	No	No	Yes	Yes
Allington and Bowen <sup>1</sup>	Yes	Yes	No	Yes	No	No
Noonan <i>et al</i> <sup>25</sup>	Yes	No	No	Yes	Yes	Yes
Price <i>et al</i> <sup>29</sup>	Yes	Yes	Yes	Yes	No	No
Katz <i>et al</i> <sup>17</sup>	Yes	Yes	Yes	Yes	No	No
Howard <i>et al</i> <sup>15</sup>	Yes	Yes	Yes	No	No	No
Wiley <i>et al</i> <sup>34</sup>	Yes	Yes	Yes	Yes	Yes	Yes
Karol <sup>16</sup>	Yes	Yes	Yes	Yes	No	N/A
Katz and Durrani <sup>18</sup>	Yes	Yes	Yes	Yes	Yes	Yes
d'Amato <i>et al</i> <sup>4</sup>	Yes	Yes	Yes	Yes	No	Yes
Danielsson and Nachemson <sup>5</sup>	Yes	No	No	Yes	No	Yes
Trivedi and Thomson <sup>32</sup>	Yes	Yes	No	Yes	No	No
Gepstein <i>et al</i> <sup>10</sup>	Yes	Yes	No	Yes	No	No
Coillard <i>et al</i> <sup>3</sup>	Yes	Yes	No	Yes	No	No
Spoonamore <i>et al</i> <sup>31</sup>	Yes	Yes	Yes	Yes	Yes	Yes
Gabos <i>et al</i> <sup>9</sup>	Yes	No	No	No	No	No

veloped, tested, and reported on by various centers. To assess the effectiveness of each orthosis and how it may compare to other orthoses available to patients with scoliosis, the need for consistent study parameters is obvious. A review of Tables 1 and 5 confirms the importance of using more consistent parameters for both patient inclusion criteria and the assessment of the effectiveness of orthotic treatment (outcomes).

Fortunately, in the more recent literature there has been a trend toward including only patients who have completed treatment and who are now known to have a significant risk for curve progression if not treated. Based on this evolution and an appreciation of the risk of progression as determined from observations of untreated patients, this committee proposes the following guidelines for future studies of orthotic treatment for AIS. We believe that until more is known about AIS and the methods to predict curve progression, such as genetic or laboratory testing, adherence to the following recommendations will facilitate our interpretation of future clinical studies.

1. A stringent, uniform criteria for patient inclusion in bracing studies must be established. Optimal inclusion criteria for future AIS brace studies con-

sist of age 10 years and older when the orthosis is prescribed, Risser 0–2, primary curve magnitude 25°–40°, no prior treatment, and, if female, either premenarchal or less than 1 year postmenarchal. The fact that some patients begin bracing shortly after they reach the age of 10 years signifies that they likely may have been noted to have scoliosis before age 10. An example of this would be a child who presents at age 7 years with a 15° curve but is not braced until 10 years of age. Such instances emphasize the need to include documentation of the patient's age when first diagnosed to categorize properly between juvenile and adolescent scoliosis. Menarchal status, curve patterns, and curve rotation should be recorded. Curve rotation can be measured using either the Nash-Moe method or the Perdriolle method, as both are reported in the orthotic literature. A template is required for Perdriolle measurements.

2. Assessment of brace effectiveness should include all of the following:
  - a. The percentage of patients who have 5° or less curve progression and the percentage of pa-

tients who have 6° or more progression at skeletal maturity.

- b. The percentage of patients who have had surgery recommended/undergone before skeletal maturity (*i.e.*, the time when the orthosis would normally have been discontinued). The surgical indications must be documented.
- c. The percentage of patients who progress beyond 45°, indicating the possible need for surgery.
- d. A minimum 2-year follow-up beyond skeletal maturity for each patient who was “successfully” treated with a brace to determine the percentage of patients who subsequently required or had surgery recommended. The surgical indications must be documented.

Efforts must be made to minimize radiographic measurement errors. Whenever possible, one observer familiar with scoliosis should make all the measurements using the same protractor. The importance of this process is clearly recognized when taking the first parameter, listed previously (2a), under consideration. Despite concerns about the accuracy of such measurements,<sup>45,46</sup> most investigators over the past decade have continued to use this parameter in their assessment of brace effectiveness.

3. Skeletal maturity should be considered achieved when <1 cm change in standing height has occurred on measurements made on 2 consecutive visits 6 months apart. If standing height measurements have not been obtained, skeletal maturity will be considered achieved when Risser 4 is present and, in females, when the patient is 2 years after menarche.
4. All patients, regardless of subjective reports on compliance, should be included in the results. This process makes “intent to treat” analysis possible (*i.e.*, all noncompliant patients who were supposed to be treated have their curve progression documented over the same time and are included in the results as if they were compliant with bracing). An “efficacy analysis,” in which those noncompliant patients can be pulled out of the results to document the efficacy of the brace in those patients able to comply, should also be considered. For compliance data to be considered completely valid, it should be measured objectively.<sup>47</sup> Currently, the data loggers required to obtain these objective measurements are used as research tools. In the future, when temperature data loggers and pressure data loggers can be economically fabricated into orthoses, then objective evidence of compliance will be routinely available.
5. All studies should provide results stratified by curve type, curve magnitude grouping, and skeletal

maturity (comparing Risser signs 0, 1, and 2) (Table 6). Subgroup analysis of these variables will strengthen the ability to compare and combine results across studies.

6. Consideration should be given to including functional and psychosocial outcome parameters in future brace studies. Only 2 of the 32 articles in this study addressed this issue, both of which were long-term follow-up studies.<sup>5,9</sup> A recommendation has been made to include the Child Health Questionnaire, the Self-image Questionnaire for Young Adolescents, and the PedsQL (Weinstein *et al* written communication, August 2004).

### ■ Key Points

- Optimal inclusion criteria for brace studies consist of: age is 10 years or older when the brace is prescribed, Risser 0–2, curves 25°–40°, and no prior treatment.
- Outcomes should be determined from: (1) the percentage of patients who have ≤5° curve progression and the percentage of patients who have ≥6° progression at maturity, (2) the percentage of patients with curves exceeding 45° at maturity and the percentage who have had surgery recommendation/undergone, and (3) 2-year follow-up beyond maturity to determine the percentage of patients who subsequently undergo surgery.
- All patients, regardless of subjective reports on compliance, should be included in the results (intent to treat).

### References

1. Allington NJ, Bowen JR. AIS: Treatment with the Wilmington brace. A comparison of full-time and part-time use. *J Bone Joint Surg Am* 1996;78-A:1056–62.
2. Carr WA, Moe JH, Winter RB, et al. Treatment of idiopathic scoliosis in the Milwaukee brace. Long term results. *J Bone Joint Surg Am* 1980;62-A:599–612.
3. Coillard C, Leroux MA, Zabjek KF, et al. SpineCor—A non-rigid brace for the treatment of idiopathic scoliosis: Post-treatment results. *Eur Spine J* 2003;12:141–8.
4. d'Amato CR, Griggs S, McCoy B. Nighttime bracing with the Providence brace in adolescent girls with idiopathic scoliosis. *Spine* 2001;26:2006–12.
5. Danielsson AJ, Nachemson AL. Radiologic findings and curve progression 22 years after treatment for AIS: Comparison of brace and surgical treatment with matching control group of straight individuals. *Spine* 2001;26:516–25.
6. Dickson RA, Weinstein SL. Bracing (and screening)—Yes or no? *J Bone Joint Surg Am* 1999;81-B:193–8.
7. Emans JB, Kaelin A, Bancel P, et al. The Boston bracing system for idiopathic scoliosis. Follow-up results in 295 patients. *Spine* 1986;11:792–801.
8. Fernandez-Feliberti R, Flynn J, Ramirez N, et al. Effectiveness of TLSO bracing in the conservative treatment of AIS. *JPO J Pract Orthod* 1995;15:176–81.
9. Gabos PG, Bojeskul JA, Bowen JR, et al. Long-term follow-up of female patients with idiopathic scoliosis treated with the Wilmington orthosis. *J Bone Joint Surg Am* 2004;86-A:1891–9.
10. Gepstein R, Leitner Y, Zohar E, et al. Effectiveness of the Charleston bending brace in the treatment of single-curve idiopathic scoliosis. *JPO J Pract Orthod* 2002;22:84–7.
11. Goldberg CJ, Dowling FE, Hall JE, et al. A statistical comparison between natural history of AIS and brace treatment in skeletally immature adolescent girls. *Spine* 1993;18:902–8.

12. Goldberg CJ, Moore DP, Fogarty EE, et al. AIS. The effect of brace treatment on the incidence of surgery. *Spine* 2001;26:42–7.
13. Green NE. Part-time bracing of AIS. *J Bone Joint Surg Am* 1986;68-A:738–42.
14. Hanks GA, Zimmer B, Nogi J. TLSO treatment of idiopathic scoliosis. An analysis of the Wilmington brace. *Spine* 1988;13:626–9.
15. Howard A, Wright JG, Hedden D. A comparative study of TLSO, Charleston, and Milwaukee braces for idiopathic scoliosis. *Spine* 1998;23:2404–11.
16. Karol LA. Effectiveness of bracing in male patients with idiopathic scoliosis. *Spine* 2001;26:2001–5.
17. Katz DE, Richards BS, Browne RH, et al. A comparison between the Boston brace and the Charleston bending brace in AIS. *Spine* 1997;22:1302–12.
18. Katz DE, Durrani AA. Factors that influence outcomes in bracing large curves in patients with AIS. *Spine* 2001;26:2354–61.
19. Lonstein JE, Winter RB. The Milwaukee brace for the treatment of AIS. A review of one thousand twenty patients. *J Bone Joint Surg Am* 1994;76-A:1207–21.
20. McCollough NC, Schultz M, Javech N, et al. Miami TLSO in the management of scoliosis: Preliminary results in 100 cases. *J Ped Orthop* 1981;1:141–52.
21. Mellencamp D, Blount W, Anderson A. Milwaukee brace treatment of idiopathic scoliosis. Late results. *Corr Farm* 1977;126:47–57.
22. Moe JH, Kettleson DA. Idiopathic scoliosis: Analysis of curve patterns and the preliminary results of Milwaukee brace treatment in 169 patients. *J Bone Joint Surg Am* 1970;52-A:1509–33.
23. Montgomery F, Willner S. Prognosis of brace-treated scoliosis. Comparison of the Boston and Milwaukee methods in 244 girls. *Acta Orthop Scand* 1989;60:383–5.
24. Nachemson AL, Peterson LE, members of Brace Study Group of the SRS. Effectiveness of treatment with a brace in girls who have AIS. *J Bone Joint Surg Am* 1995;77-A:815–22.
25. Noonan KJ, Weinstein SL, Jacobson WC, et al. Use of the Milwaukee brace for progressive idiopathic scoliosis. *J Bone Joint Surg Am* 1996;78-A:557–61.
26. Olafsson Y, Saroste H, Sodeolund V, et al. Boston brace in the treatment of idiopathic scoliosis. *JPO J Pract Orthod* 1995;15:524–7.
27. Peltonen J, Poussa M, Ylikoski M. Three-year results of bracing in scoliosis. *Acta Orthop Scand* 1988;59:487–90.
28. Piazza MR, Bassett GS. Curve progression after treatment with the Wilmington brace for idiopathic scoliosis. *JPO J Pract Orthod* 1990;10:39–43.
29. Price CT, Scott DS, Reed FR, et al. Nighttime bracing for AIS with the Charleston bending brace: Long-term follow-up. *JPO J Pract Orthod* 1997;17:703–7.
30. Rowe DE, Bernstein SM, Riddick MF, et al. A meta-analysis of the efficacy of non-operative treatments for idiopathic scoliosis. *J Bone Joint Surg Am* 1997;79-A:664–74.
31. Spoonamore MJ, Dolan LA, Weinstein SL. Use of the Rosenberger brace in the treatment of progressive AIS. *Spine* 2004;29:1458–64.
32. Trivedi JM, Thomson JD. Results of Charleston bracing in skeletally immature patients with idiopathic scoliosis. *JPO J Pract Orthod* 2001;21:277–80.
33. Upadhyay SS, Nelson IW, Ho EK, et al. New prognostic factors to predict the final outcome of brace treatment in AIS. *Spine* 1995;20:537–45.
34. Wiley JW, Thomson JD, Mitchell TM, et al. Effectiveness of the Boston brace in treatment of large curves in AIS. *Spine* 2000;25:2326–32.
35. Willers U, Normelli H, Aaro S, et al. Long-term results of Boston brace treatment on vertebral rotation in AIS. *Spine* 1993;18:432–5.
36. Bunnell WP. The natural history of idiopathic scoliosis. *Clin Orthop Relat Res* 1988;229:20–5.
37. Bunnell WP. The natural history of idiopathic scoliosis before skeletal maturity. *Spine* 1986;11:773–6.
38. Lonstein JE. Natural history and school screening for scoliosis. *Orthop Clin North Am* 1988;19:227–37.
39. Lonstein JE, Carlson JM. The prediction of curve progression in untreated idiopathic scoliosis during growth. *J Bone Joint Surg Am* 1984;66-A:1061–71.
40. Peterson LE, Nachemson AL. Prediction of progression of the curve in girls who have adolescent idiopathic scoliosis of moderate severity. *J Bone Joint Surg Am* 1995;77-A:823–7.
41. Weinstein SL. Adolescent idiopathic scoliosis: Prevalence and natural history. *Instr Course Lect* 1989;38:115–28.
42. Weinstein SL. Natural history. *Spine* 1999;24:2592–600.
43. Nachemson A, Lonstein J, Weinstein S. Report of the SRS Prevalence and Natural History Committee, 1982. Paper presented at: SRS Annual Meeting; September 1982; Denver, CO.
44. Little DG, Song KM, Katz D, et al. Relationship of peak height velocity to other maturity indicators in idiopathic scoliosis in girls. *J Bone Joint Surg Am* 2000;82-A:685–93.
45. Carman DL, Browne RH, Birch JG. Measurement of scoliosis and kyphosis radiographs. Intraobserver and interobserver variation. *J Bone Joint Surg Am* 1990;72-A:328–33.
46. Morrissy RT, Goldsmith GS, Hall EC, et al. Measurement of the Cobb angle on radiographs of patients who have scoliosis. Evaluation of intrinsic error. *J Bone Joint Surg Am* 1990;72-A:320–7.
47. Havey R, Gavin T, Patwardhan A, et al. A reliable and accurate method for measuring orthosis wearing time. *Spine* 2002;27:211–4.